Clarity Pharmaceuticals (ASX: CU6) shares are up around 12% today (at the time of writing), extending a strong run that has seen the share price rise roughly 41% over the past year.
Why are Clarity shares rising?
The catalyst for today’s move was Clarity’s announcement of a large-scale manufacturing agreement with US-based company Theragenics, which gives Clarity access to a 134,000 square foot production facility with 14 cyclotrons capable of producing copper 64 at scale.
Why this matters
This is a meaningful step for a company transitioning from clinical development toward potential commercialisation.
Clarity’s lead prostate cancer imaging product is currently in Phase III trials. As the company moves closer to potential approval, the focus increasingly shifts from clinical progress to execution.
Manufacturing capacity is a critical part of that equation.
This agreement strengthens Clarity’s supply footprint in the US and builds on its existing network of manufacturing partners. It positions the company to meet potential demand across large oncology markets if its product reaches approval.
Theragenics alone has the capacity to produce enough copper 64 for around 2,000 patient doses per day per cyclotron.
That level of output reflects readiness for commercial scale rather than just clinical supply.
The structural advantage
According to the company, Copper 64 offers a key advantage over traditional isotopes due to its longer half life of around 12.7 hours, enabling a shelf life of up to 48 hours.
This allows for centralised manufacturing and broader distribution, reducing logistical constraints that have historically limited the radiopharmaceutical market.
It also supports a more efficient and scalable operating model, which becomes increasingly important as volumes grow.
What investors should watch
Today’s share price reaction reflects growing investor confidence in Clarity’s ability to execute beyond the clinical stage.
The company is building the infrastructure required to support a commercial launch, an area that can often become a bottleneck if left too late.
However, the core risk remains unchanged. The lead product is still unapproved, and regulatory outcomes will ultimately determine the size of the opportunity.
For now, though, there is plenty of optimism as Clarity evolves from a clinical stage story into a company preparing for scale.
The post Clarity Pharmaceuticals shares are up 12% today. Here’s what’s driving the move appeared first on The Motley Fool Australia.
Should you invest $1,000 in Clarity Pharmaceuticals right now?
Before you buy Clarity Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Clarity Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 3 ASX healthcare stocks tipped to soar over 100% higher this year
- Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares
- Exciting clinical news for this ASX healthcare stock earns it a buy recommendationÂ
- 5 things to watch on the ASX 200 on Wednesday
- Why is this ASX 300 stock rocketing 17% today?
Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.